Nearly 300 medicines are expected to see their retail prices reduced as part of Morocco’s reform of its drug pricing system. The announced reductions range from 10% to 70%, just weeks after the new regulatory decree came into force.
The reform is based on Decree No. 2.25.631, dated July 23, 2026, and published in the Official Gazette on August 6. The decree modifies a system that has been in place since 2013 and now provides for a periodic review of prices every three years, compared with five years previously.
The international price comparison mechanism has also been revised. For medicines whose ex-factory price excluding tax exceeds MAD 300, the lowest price recorded in the reference countries will now be used. For medicines with an ex-factory price excluding tax of MAD 300 or less, the average of reference prices will continue to apply.
More Frequent Price Reviews
Medicines already marketed will have to be reassessed within 12 months of the new system taking effect. The first list covers nearly 300 products, with reductions reaching as much as 70% for some medicines.
The reform directly changes the economic parameters of the pharmaceutical market, particularly for laboratories, distributors and pharmacies. It also aims to bring prices in Morocco closer to the international reference prices established under the new mechanism.
The first wave of reductions marks the operational phase of the reform. Further reviews are expected to follow, gradually extending the new framework to medicines marketed on the Moroccan market.
